Phase II study of prolonged oral etoposide in refractory ovarian cancer

Keyphrases

• Phase I Study 100%
• Oral Etoposide 100%
• Refractory Ovarian Cancer 100%
• Median Survival 50%
• Dose-limiting Toxicity 50%
• Neutropenia 50%
• Myelosuppression 50%
• Etoposide 50%
• Objective Response 50%
• Drug-resistant Tumor 50%
• Neurotoxicity 50%
• Dosing Schedule 50%
• Blood Test 50%
• Calculated Dose 50%
• Number of Prior Regimens 50%
• Cardiovascular Toxicity 50%
• Platin 50%
• Taxoids 50%
• Schedule Algorithm 50%
• Poorly Differentiated Tumors 50%
• Number of Capsules 50%

Medicine and Dentistry

• Ovarian Cancer 100%
• Etoposide 100%
• Oral 100%
• Tumor 66%
• Neutropenia 33%
• Drug Dose Regimen 33%
• Bone Marrow Suppression 33%
• Cardiovascular Toxicity 33%
• Taxoid 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Ovary Cancer 100%
• Etoposide 100%
• Neutropenia 33%
• Bone Marrow Suppression 33%
• Cardiovascular Toxicity 33%
• Taxoid 33%